8968 results about "Benzoic acid" patented technology

A premium synthetic lubricant having antiwear properties comprises a synthetic isoparaffinic hydrocarbon base stock and an effective amount of at least one antiwear additive. The antiwear additive is preferably at least one of a metal phosphate, a metal dialkyldithiophosphate, a metal dithiophosphate a metal thiocarbamate, a metal dithiocarbamate, an ethoxylated amine dialkyldithiophosphate and an ethoxylated amine dithiobenzoate. Metal dialkyldithiophosphates are preferred, particularly zincdialkyldithiophosphate (ZDDP). The base stock is derived from a waxy, Fischer-Tropsch synthesized hydrocarbon feed fraction comprising hydrocarbons having an initial boiling point in the range of about 650-750 DEG F., by a process which comprises hydroisomerizing the feed and dewaxing the isomerate. The lubricant may also contain hydrocarbonaceous and synthetic base stock material in admxture with the Fischer-Tropsch derived base stock.

A fragrance delivery system which releases fragrant alcohols upon exposure to light. The system comprises 2-benzoyl benzoates of general formulae which can comprise various subtituents R1-R5 as defined in the application and a substituted R* which is the organic part of a fragrant alcohol.

The present invention relates to a process of providing the 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid in substantially free form (Compound 1).

These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of systemically administered compositions which include primary amine derivatives of benzoic acid as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering the aldehyde and/or ketone products of lipid peroxidation. Increased levels of lipid peroxidation have been repeatedly demonstrated as a part of the non-enzymatic "inflammatory cascade" process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid (or PABA) is an example of the primary therapeutic agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group that reacts with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods. The carbonyl sequestering agents are used in combination with at least one co-agent so as to produce an additional beneficial physiological effect of an anti-inflammatory nature. Such compositions are administered systemically entirely via the oral route. Co-agents of the present invention include anti-oxidants and free radical trapping compounds (e.g., alpha-tocopherol), compounds having indirect anti-oxidant activity (e.g., selenium), vitamins (e.g., pyridoxine HCl), compounds which facilitate kidney drug elimination (e.g., glycine), metabolites at risk of depletion (e.g., pantothenic acid), sulfhydryl containing chemicals (e.g., methionine), compounds which facilitate glutathione activity (e.g., N-acetylcysteine), and non-absorbable polyamine co-agents (e.g., chitosan).

Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.

One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand. In certain embodiments, a ligand is bound to only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, both of the oligonucleotide strands of the double-stranded oligonucleotide independently comprise a bound ligand. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. In certain embodiments, a phosphate linkage in one or both of the strands of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5β-cholanic acid. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety. In certain embodiments, a phosphate linkage of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5β-cholanic acid. The ligand improves the pharmacokinetic properties of the oligonucleotide.

The invention provides a magnesium halide addition compound shown as general formula MgX2-mROH-nE-pH2O, wherein, X refers to chlorine or bromine, R refers to the alkyl of C1-C12; naphthene base of C3-C10 or the aryl of the C6-C10; E refers to o-alkoxybenzoic ether compound shown in the general formula (II); m ranges from 1 to 5; n ranges from 0.005 to 1.0; and P ranges from 0 to 0.8.

A microbicidal composition containing: (a) 1,2-benzisothiazolin-3-one; and (b) at least one microbicide selected from among benzalkonium chloride, benzethonium chloride, benzyl alcohol, caprylyl glycol, chlorphenesin, 2,2′-dithiobis(N-methylbenzamide), diazolidinyl urea, ethylenediamine tetraacetic acid, ethylparaben, imidazolidinyl urea, methylparaben, phenoxyethanol, linoleamidopropyl PG-dimonium chloride phosphate, cocamidopropyl PG-dimonium chloride phosphate, propylparaben, cis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride, dehydroacetic acid or its salts, benzoic acid or its salts, sodium hydroxymethylglycinate and zinc pyrithione.

The invention discloses 2-pyridine-oxyl(sulfide) benzoyloxy enoates compound with general formula(I, II); wherein X is H or S; R1 is H, halogen, or 4,6- dimethoxy pyrimidine-2- radicel or one of the following groups; methyls on N-O bonds and double bonds are in maleinoid form or anti form; R2,R3,R4,R6,R7 are selected from H or alkyl from C1-C6; R5 is alkyl from C1-C6, alcoxyl-alkyl from C2-C6, alkenyl from C3-C6 or alkynyl from C3-C6; radicals of R6 and R7 are in maleinoid form or anti form; R8 is alkyl from C1-C6, alkenyl from C3-C6 or alkynyl from C3-C6. The compound (I, II)is of activity in weeding and is safe to crops like soybean, cotton, earthnut, cole, corn, etc.

A 5-(3-cyanophenyl)-3-formylbenzoic acid compound of the formula (IV) is prepared by reacting a 5-bromo-3-(hydroxymethyl)benzoic acid compound of the formula (I) with manganese dioxide to provide a 5-bromo-3-formylbenzoic acid compound of the formula (II), and then reacting the resultant compound of the formula (II) with 3-cyanophenylboronic acid of the formula (III) in the presence of a palladium complex.

R is a H atom or a C₁-C₁₀ alkyl group.

The present invention relates to a substantially a solid form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1, Solvate Form A and Compound 1, HCl Salt Form A), processes for making such forms, pharmaceutical compositions thereof, and methods of treatment therewith.

The present invention relates to formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid in Form I, pharmaceutical packs or kits thereof, and methods of treatment therewith.

The present invention provides a therapeutic or prophylactic agent as a substitute for conventional steroids or immunosuppressive agents to treat or prevent systemic erythematosus, glomerulonephritis, lupus nephritis, idiopathic thrombocytopenic purpura or autoimmune anemia. The agent comprises a retinoic acid receptor agonist, specifically a retinoic acid receptor subtype alpha (RARalpha) agonist, including for example:(1) carboxylic acid compounds having condensed rings represented by the following formula: (wherein the rings L and M are condensed, are the same as or different from each other, and represent an aromatic hydrocarbon which may have a substituent group or a heterocycle which may have a substituent group; the rings A and B are independent of each other and represent an aromatic hydrocarbon ring or heterocycle which may have a substituent group; and D represents a carboxyl group which may have a protective group),(2) 4-{[(3,5-bistrimethylsilylphenyl)carbonyl]amino}benzoic acid, 4-{2-[5-(3-methoxymethyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-yl)pyrrolyl]}benzoic acid, etc.

The present invention relates to a novel feed composition for animals, for example poultry, comprising as active ingredient benzoic acid, derivatives or metabolites thereof, in combination with a mixture of at least two active compounds selected from the group consisting of thymol, eugenol and piperine. The inventors found that in addition to the well known function of benzoic acid, this compound can be used as a potential growth promoter when it is combined with a mixture of at least two active compounds selected from the group consisting of thymol, eugenol and piperine. In particular the inventors have been able to demonstrate that a mixture of these chemical compounds present in different parts of plants, used in synergy and in combination with an appropriate amount of benzoic acid, exhibits, in totally unexpected manner, the effects sought by the present invention of improving the digestibility of poultry feed, i.e. for improving feed conversion ratio and/or daily weight gain in animal.

The object is to provide a polyimide ink composition having good printing properties and good continuous printing properties, which composition can be dried at a low temperature of not higher than 220° C., and which composition gives a coating film, after being dried, having excellent dimensional stability, heat resistance, low modulus of elasticity, flexibility, resistance to warping, chemical resistance, adhesiveness with substrates, and plating resistance. This object is accomplished by a polyimide ink composition for printing, comprising a mixed solvent containing an benzoic acid ester solvent and a glyme solvent, and a polyimide soluble in the mixed solvent; wherein the polyimide is obtained by polycondensing a polyimide oligomer with a tetracarboxylic dianhydride component(s) and/or a diamine component(s) having no siloxane bond in molecular skeleton thereof the polyimide oligomer being prepared by polycondensing a tetracarboxylic dianhydride component(s) and a diamine component(s) having siloxane bonds in molecular skeleton thereof in the presence of a base catalyst(s), or a mixed catalyst including a lactone(s) and/or an acidic compound(s) and a base(s); the content of the diamine component(s) having siloxane bonds based on the total diamine components being 15 to 85% by weight.

An N-acyl anthranilic acid derivative represented by general formula (1) or a salt thereof is useful for prevention or treatment of diseases associated with excessive production of collagen. (In the formula, R¹ represents a carboxyl group or the like; R² represents a hydrogen atom or the like; R³ represents an optionally substituted aryl group or the like; X¹ represents a carbonyl group; X² represents a bonding hand; X³ represents a bonding hand; X⁴ represents a bonding hand or the like; and A represents an optionally substituted phenyl group or the like.)

The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.